Article info
Poster Presentations
Rheumatoid arthritis - etiology, pathogenesis and animal models
FRI0048 The ANTI-CD20 antibody rituximab reduces the inflammatory and prothrombotic profile of leukocytes from rheumatoid arthritis patients and modulates the activity of endothelial cells
Citation
FRI0048 The ANTI-CD20 antibody rituximab reduces the inflammatory and prothrombotic profile of leukocytes from rheumatoid arthritis patients and modulates the activity of endothelial cells
Publication history
- First published June 15, 2017.
Online issue publication
January 09, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions